Actively Recruiting
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Led by Novartis Pharmaceuticals · Updated on 2026-04-07
130
Participants Needed
30
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
CONDITIONS
Official Title
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent or assent according to local guidelines before enrollment
- Patient with sickle cell disease currently enrolled in a Novartis-sponsored crizanlizumab study and benefiting from treatment as judged by the investigator
- Completed the treatment schedule as planned in the parent study
- Demonstrated compliance with visit schedules in the parent study and willingness to comply with future visits
You will not qualify if you...
- Patient permanently discontinued crizanlizumab treatment before completing the parent study
- Ongoing or unresolved treatment-related Grade 3 or higher adverse events, or any ongoing adverse event requiring dose interruption
- Participation in any other investigational clinical trial besides the parent study, or plans to participate in another trial
- Pregnant or nursing women
- Women of childbearing potential unwilling to use highly effective contraception during treatment and for 15 weeks after stopping crizanlizumab
- Patients not meeting parent study criteria to continue crizanlizumab treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 30 locations
1
University Of Alabama
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
Childrens National Hospital
Washington D.C., District of Columbia, United States, 20010
Active, Not Recruiting
3
Augusta University Georgia
Augusta, Georgia, United States, 30912
Actively Recruiting
4
East Carolina University
Greenville, North Carolina, United States, 27834
Completed
5
East Carolina University
Greenville, North Carolina, United States, 27858
Completed
6
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104-4399
Active, Not Recruiting
7
Cook Childrens Medical Center
Fort Worth, Texas, United States, 76104
Completed
8
Novartis Investigative Site
Brussels, Belgium, 1000
Completed
9
Novartis Investigative Site
Laken, Belgium, 1020
Active, Not Recruiting
10
Novartis Investigative Site
Liège, Belgium, 4000
Active, Not Recruiting
11
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil, 41253-190
Active, Not Recruiting
12
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil, 14051-140
Active, Not Recruiting
13
Novartis Investigative Site
São Paulo, São Paulo, Brazil, 01232-010
Active, Not Recruiting
14
Novartis Investigative Site
Valledupar, Cesar Department, Colombia, 200001
Actively Recruiting
15
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia, 760032
Active, Not Recruiting
16
Novartis Investigative Site
Montería, Colombia, 230004
Active, Not Recruiting
17
Novartis Investigative Site
Créteil, France, 94010
Completed
18
Novartis Investigative Site
Paris, France, 75015
Active, Not Recruiting
19
Novartis Investigative Site
Paris, France, 75015
Completed
20
Novartis Investigative Site
Heidelberg, Germany, 69120
Active, Not Recruiting
21
Novartis Investigative Site
Padova, PD, Italy, 35128
Active, Not Recruiting
22
Novartis Investigative Site
Orbassano, TO, Italy, 10043
Completed
23
Novartis Investigative Site
Beirut, Lebanon, 113-0236
Actively Recruiting
24
Novartis Investigative Site
Tripoli, Lebanon, 1434
Actively Recruiting
25
Novartis Investigative Site
Khoudh, Oman, 123
Actively Recruiting
26
Novartis Investigative Site
Barcelona, Spain, 08035
Completed
27
Novartis Investigative Site
Madrid, Spain, 28009
Active, Not Recruiting
28
Novartis Investigative Site
Hatay, Antakya, Turkey (Türkiye), 31101
Withdrawn
29
Novartis Investigative Site
Adana, Saricam, Turkey (Türkiye), 01330
Active, Not Recruiting
30
Novartis Investigative Site
Adana, Yuregir, Turkey (Türkiye), 01250
Active, Not Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here